Definition
Market Access
Market access is the work of securing coverage, reimbursement and appropriate pricing for a drug or medical device so that the patients it is approved for can obtain it, spanning payer strategy, pricing, contracting and evidence of value.
2 min readReviewed September 14, 2026
Also known as: Pricing and market access, Payer access, Market access strategy
What is market access?
FDA approval makes a product legal to sell, but it does not guarantee that payers will cover it or that patients can afford it. Market access teams work to close that gap by persuading payers, pharmacy benefit managers, health systems and government programs to cover a product on reasonable terms.
In the United States, access is fragmented across commercial plans, Medicare Part B and Part D, Medicaid and other programs, each with different rules. Outside the United States, access typically runs through national or regional health technology assessment (HTA) bodies and government price negotiations.
What market access teams work on
The function usually spans several disciplines:
- Pricing strategy: setting launch list price and planning discounts, rebates and government price reporting such as Average Manufacturer Price, Best Price and Average Sales Price.
- Payer strategy and contracting: negotiating formulary position, tier placement and utilization management criteria with pharmacy benefit managers and health plans.
- Evidence and value: health economics and outcomes research (HEOR), budget impact models and formulary dossiers for pharmacy and therapeutics committees.
- Coding and coverage: HCPCS codes, Medicare national and local coverage determinations, and hospital outpatient pass-through status for medical benefit products.
- Trade and distribution: wholesaler, specialty pharmacy and group purchasing organization agreements.
- Patient services: hub programs, copay assistance and patient assistance programs.
Why market access matters
Access often determines commercial success as much as the label does. A drug with broad coverage and few restrictions can reach patients quickly, while a drug that is excluded or subject to strict prior authorization may see slow uptake even with strong clinical data.
Market access questions are data questions: which plans cover a drug and on what tier, how many covered lives each plan represents, which accounts buy through 340B or GPO contracts, how net price compares across channels, and where competitors hold preferred status. Policy changes such as the Medicare Drug Price Negotiation Program, the Part D redesign and state PBM laws keep shifting those answers.